This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Thymus흉선의 악성신생물 (흉선암)

📋 Contents and key points
A. Classification codesICD-10 C37 (malignant neoplasm of thymus; includes thymoma)
B. SynonymsThymic cancer, thymoma, malignant thymoma, thymic epithelial tumor (thymoma, thymic carcinoma, thymic epithelial tumor, TET)
C. Adult onsetVery high — occurs mainly in adults in their 40s–60s; extremely rare in children and adolescents
Special Copayment ReductionV193 · 5 years from the cancer patient registration date · 5% copayment
1. HistoryHistorical descriptions of mediastinal tumors; development of the WHO classification system; establishment of the association with myasthenia gravis
2. CausesMostly unknown cause; radiation exposure, autoimmune predisposition; possible partial association with asbestos exposure
3. GeneticsGTF2I variants (type A), CDKN2A, TP53, EGFR amplification (thymic carcinoma); differences in genomic profiles by WHO type
4. EpidemiologyRare tumor; incidence about 0.13–0.32/100,000; the most common type of anterior mediastinal tumor
5. PathophysiologyOriginates from thymic epithelial cells; dysregulation of lymphocyte maturation and immune tolerance; accompanied by autoimmune syndromes
6. SymptomsAnterior mediastinal compression symptoms (cough, chest pain, dyspnea); myasthenia gravis symptoms; SVC syndrome
7. SignsPtosis, diplopia, muscle weakness (MG); SVC syndrome; widened anterior mediastinal shadow on chest X-ray
8. ScreeningNo standard screening test; chest CT in MG patients; incidental detection is common
9. DiagnosisChest CT/MRI, tissue biopsy (CT-guided needle biopsy, mediastinoscopy, VATS), WHO classification pathology, Masaoka staging
10. TreatmentComplete resection (first line), adjuvant radiotherapy, cisplatin-based chemotherapy, octreotide, pembrolizumab
11. PrognosisTypes A–AB very favorable; types B2–B3 intermediate; thymic carcinoma poor prognosis; completeness of resection is the strongest prognostic factor
12. PreventionNo known prevention; consider early chest CT in patients with autoimmune disease; early diagnosis of MG is important
13. ReferencesWHO 2021 classification of thymic tumors, NCI PDQ, Annals of Thoracic Surgery, NCCN guidelines

1. History

Malignant neoplasms of the thymus, namely thymoma and thymic carcinoma, are rare thoracic tumors, but they are the most common type of tumor arising in the anterior mediastinum. Systematic understanding of the thymus began in the early 20th century, when the thymus was found to play a key role in immune function and lymphocyte maturation. Cases of thymoma began to be reported in the clinical literature from the early 1900s, but because no pathologic classification had been established at the time, various terms were used interchangeably.

The association between thymoma and myasthenia gravis (MG) was first described by Laquer and Weigert in 1901, and its clinical importance grew after thymectomy was found to be effective for MG in the 1930s–1940s. In 1939, Alfred Blalock reported symptom improvement after thymectomy in an MG patient, clinically demonstrating the relationship between the thymus and autoimmune disease.

The pathologic classification system has changed over decades. After the classifications proposed by Bernatz (1961), Moran (1993) and others, the World Health Organization (WHO) published a standard classification of thymic epithelial tumors in 2004 (type A, AB, B1, B2, B3 thymoma and thymic carcinoma). The 4th edition of the WHO classification in 2015 presented refined histologic and immunohistochemical criteria, and the revised 2021 WHO classification integrated the latest pathologic and molecular findings. For surgical staging, the Masaoka stage (proposed in 1981 and later revised as Masaoka-Koga) has been widely used, and recently the ITMIG/IASLC TNM staging system is used in parallel.

2. Causes

The exact cause of thymoma and thymic carcinoma is mostly unknown (idiopathic). Unlike other malignancies, clear environmental risk factors have rarely been established, so research into the pathogenesis is ongoing.

There are reports that radiation exposure may contribute to thymoma development, but a causal relationship has not been clearly proven in large epidemiologic studies. Reports have accumulated of thymic tumors developing decades after radiotherapy given in the past for thymic enlargement in children. There is also limited evidence from some studies that asbestos exposure may be associated with an increased risk of thymoma, but it is not as strong as the association with mesothelioma.

Autoimmune predisposition may be associated with thymoma development. Myasthenia gravis accompanies 30–45% of thymoma patients, and the coexistence of various autoimmune diseases such as pure red cell aplasia, hypogammaglobulinemia (Good syndrome), systemic lupus erythematosus and rheumatoid arthritis suggests an interrelationship between impaired immunoregulatory function of the thymus and tumor development. In particular, detection of acetylcholine receptor antibodies (AChR-Ab) in thymoma patients shows that an abnormal immune response within the thymus mediates myasthenia gravis.

Racial differences are also observed, with somewhat higher thymoma incidence reported in Asian and Black people than in White people. Sex differences are small, but some studies report a slightly higher incidence in women. As for genetic factors, most cases are sporadic and familial clusters are extremely rare.

3. Genetics

The genomic profiles of thymic epithelial tumors differ markedly by histologic subtype. In type A thymoma, the L424H point mutation of the GTF2I (General Transcription Factor 2I) gene is found in about 80%, a molecular marker highly specific to type A. GTF2I variants are known to regulate cell proliferation and survival signaling pathways.

In type B thymoma, the frequency of GTF2I variants is low; instead, RAS pathway variants such as HRAS, NRAS or variants in DNA damage repair genes are observed. In thymic carcinoma (type C), TP53 variants, CDKN2A deletion, EGFR amplification and variants, KIT (CD117) variants and PIK3CA variants have been reported, showing a far more complex and unstable genome than thymoma.

Tumor mutational burden (TMB) is low in thymoma but may be somewhat higher in thymic carcinoma. PD-L1 expression can be observed in both thymoma and thymic carcinoma, but a clinical consideration is that response to immune checkpoint inhibitors is not necessarily proportional to PD-L1 expression. In thymoma in particular, the risk of immune-related adverse events such as exacerbation of myasthenia gravis and myocarditis is high with immune checkpoint inhibitors, so they must be applied cautiously.

Recent RNA sequencing-based molecular subtyping studies have shown that thymomas can be reclassified into 4 groups—types A/AB, type B1, types B2/B3, and thymic carcinoma—each with different gene expression patterns and clinical courses. This molecular classification is expected to form the basis for future development of targeted therapies.

4. General epidemiology

Thymic epithelial tumors are very rare among all tumors, with an estimated incidence of about 0.13–0.32 per 100,000 population per year. They are the most common type of anterior mediastinal tumor, accounting for about 20% of anterior mediastinal tumors in adults. About 400–500 new cases are diagnosed annually in the United States, and in Korea, though rare, it is one of the important thoracic tumors occurring in middle-aged adults.

The median age at onset is about 50–60 years, and occurrence before age 40 is relatively rare. Sex differences are small, but some studies report a somewhat higher incidence in women. The distribution of histologic types by WHO classification is, in order, type AB most common (about 28%), followed by B2 (about 24%), B3 (about 16%), A (about 13%), B1 (about 11%), and thymic carcinoma (about 8%).

Myasthenia gravis accompanies about 30–45% of thymoma patients, and thymoma is found in about 10–15% of all myasthenia gravis patients. Pure red cell aplasia accompanies about 5% of thymoma patients and hypogammaglobulinemia (Good syndrome) about 5–10%. Thymic carcinoma is rarer than thymoma and shows a more aggressive clinical course and poorer prognosis.

5. Pathophysiology

Thymic epithelial tumors originate from cortical and medullary epithelial cells of the thymus. The normal thymus is an organ essential for T lymphocyte maturation and establishment of immune tolerance, eliminating self-reactive T cells through positive and negative selection of immature T cells (thymocytes). Neoplastic transformation of thymic epithelial cells impairs this immunoregulatory function.

The pathophysiology of myasthenia gravis is closely linked to an abnormal immune response within the thymus. Within thymoma, self-reactive T cells against proteins structurally similar to the acetylcholine receptor (AChR) of the neuromuscular junction mature, and these help B cells produce autoantibodies against AChR. These autoantibodies block or destroy AChR at the neuromuscular junction, causing muscle weakness.

At the molecular level, the GTF2I L424H variant (type A thymoma) is known to activate the PI3K/AKT signaling pathway, promoting cell proliferation and survival. TP53 variants and CDKN2A deletion observed in thymic carcinoma cause cell cycle dysregulation, and KIT variants promote tumor growth through constitutive activation of the SCF-KIT pathway. Thus, progression from thymoma to thymic carcinoma is understood as resulting from gradual accumulation of genomic instability.

Thymic epithelial tumors show very different clinical features depending on the degree of invasion. Types A and AB are mostly confined within the capsule, so prognosis after complete resection is very favorable. In contrast, type B3 and thymic carcinoma often invade surrounding structures (pericardium, lung, pleura, great vessels), and pleural dissemination and distant metastasis can also occur.

6. Symptoms

About 30–40% of thymomas are found incidentally on chest X-ray or CT without symptoms. The rest are diagnosed through compression symptoms from the anterior mediastinal tumor or symptoms of an associated autoimmune disease.

Mediastinal compression symptoms

Myasthenia gravis (MG)-related symptoms

Other paraneoplastic syndromes

With pure red cell aplasia, anemia-related fatigue and shortness of breath appear, and with hypogammaglobulinemia (Good syndrome), recurrent bacterial infections occur. Rarely, autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and polymyositis may accompany it.

7. Signs

General physical findings

Many patients have no specific physical signs. With a large tumor, decreased breath sounds over the upper lung on chest auscultation and dullness on percussion may be observed. With SVC syndrome, jugular venous distension, swelling of the face, neck and upper limbs, and redness and shininess of the skin appear, and headache and dizziness worsen when bending the upper body forward.

Myasthenia gravis-related signs

On physical examination, ptosis is observed and may be unilateral or bilateral. Limited eye movement due to extraocular muscle paralysis is confirmed. Cogan lid twitch sign (the eyelid briefly twitches upward and then falls when shifting gaze from downward to straight ahead) is a finding specific to MG. Muscle strength testing shows decreased strength after repeated muscle contraction (fatigability). The ice pack test is a simple bedside test confirming improvement of ptosis after applying an ice pack.

Imaging findings

Chest X-ray may show irregular widening of the anterior mediastinal shadow, and chest CT shows an encapsulated or infiltrative soft tissue mass in the anterior mediastinum. Calcification, cystic change and necrosis may be present.

8. Screening

Standard screening for thymoma is currently not recommended. This is because thymoma incidence is so low that the cost-effectiveness of screening the general population has not been demonstrated.

However, in patients with myasthenia gravis, chest CT is recommended as standard care to check for an associated thymic lesion. Because thymoma is found in about 10–15% of MG patients, imaging including chest CT must be performed at MG diagnosis. Chest CT should also be considered when pure red cell aplasia, hypogammaglobulinemia or other thymus-related autoimmune diseases are suspected.

Because about 30–40% of thymomas are found incidentally without symptoms on chest X-ray or chest CT performed for other reasons, further testing should be done immediately when an anterior mediastinal mass is found clinically. The differential diagnosis of anterior mediastinal tumors includes, besides thymoma, lymphoma, germ cell tumors and retrosternal thyroid tumors.

9. Diagnosis

Imaging diagnosis

Chest CT (contrast-enhanced) is the basic test for evaluating anterior mediastinal tumors. It assesses tumor size, shape, capsular integrity and invasion of surrounding structures. An intact capsule suggests a higher likelihood of thymoma, while an irregular capsule or invasion of surrounding tissue suggests invasive thymoma or thymic carcinoma. MRI is superior to CT for assessing vascular, pericardial and soft tissue invasion and is particularly useful for preoperative planning. PET-CT is used to assess distant metastasis and to stage thymic carcinoma.

Tissue diagnosis

Definitive diagnosis is made by histopathologic examination. Preoperative tissue biopsy methods include CT-guided percutaneous core needle biopsy, mediastinoscopy, thoracoscopy (VATS), or anterior mediastinotomy (Chamberlain procedure). When surgical resection is planned, proceeding directly to surgical resection without tissue biopsy is sometimes preferred.

Pathologic classification and staging

According to the WHO 2021 classification, tumors are classified as type A, AB, B1, B2, B3 thymoma and thymic carcinoma. The Masaoka-Koga stage, based on the degree of invasion, is as follows:

StageCriteria
Stage IConfined within the capsule, no capsular invasion
Stage IIAMicroscopic capsular invasion
Stage IIBMacroscopic capsular invasion or invasion of extracapsular fat
Stage IIIInvasion of neighboring organs (pericardium, great vessels, lung)
Stage IVAPleural or pericardial dissemination
Stage IVBLymph node or hematogenous distant metastasis

Blood tests

To check for associated myasthenia gravis, acetylcholine receptor antibody (AChR-Ab) and anti-MuSK antibody testing are performed. Hematologic tests to evaluate pure red cell aplasia and measurement of immunoglobulin levels may also be needed.

10. Treatment

Surgery

Complete resection is the most important treatment for thymic epithelial tumors and the strongest prognostic factor. When complete resection is possible, surgery is the first-line treatment, and extended resection including the thymus and surrounding fat tissue is performed. When myasthenia gravis is present, MG symptoms often improve after thymectomy. Recently, minimally invasive thymectomy using robotic assistance or VATS has been performed in stages I–IIA with results equivalent to open surgery.

Radiation therapy

After complete resection, postoperative adjuvant radiotherapy is recommended for types B2–B3 or stages II–III. When resection is not possible, definitive radiotherapy or concurrent chemoradiotherapy is given. In thymic carcinoma, postoperative adjuvant radiotherapy is regarded as nearly standard.

Chemotherapy

In unresectable or recurrent/metastatic disease, cisplatin, doxorubicin, cyclophosphamide (PAC regimen) is most commonly used as first-line chemotherapy. Carboplatin+paclitaxel combination is also used. Neoadjuvant chemotherapy is used to downstage borderline resectable or unresectable tumors.

Targeted therapy and immunotherapy

In thymic carcinoma with a KIT (CD117) variant, KIT inhibitors such as imatinib may be considered. Pembrolizumab can be used alone in thymic carcinoma that has failed prior treatment, but in thymoma it must be applied cautiously because of the risk of serious immune-related adverse events such as exacerbation of myasthenia gravis and myocarditis. There are also reports that a somatostatin analogue (octreotide) shows some efficacy in thymoma.

11. Prognosis

The prognosis of thymoma differs greatly by WHO type and completeness of surgical resection. When complete resection is achieved, most show a favorable long-term prognosis.

WHO type10-year survivalInvasion frequency
Type A90~100%Capsular invasion 0%
Type AB85~95%Capsular invasion 6%
Type B180~90%Invasion 19%
Type B260~75%Invasion 25%
Type B350~65%Invasion 42%
Thymic carcinoma30~40%Invasion 89%

5-year survival by Masaoka stage is reported as about 96% for stage I, about 86% for stage II, about 69% for stage III, about 50% for stage IVA, and about 11% for stage IVB. Thymic carcinoma is often already advanced at diagnosis, so its 5-year survival rate of about 30–50% is markedly lower than that of thymoma. Recurrence mainly takes the form of pleural dissemination, and early stage and completeness of resection are important predictors of recurrence.

When myasthenia gravis is present, complete remission is achieved in about 30–40% after thymectomy, and symptom improvement is seen in most. However, MG symptoms may persist or recur even after thymectomy, so continued neurologic monitoring is needed.

12. Prevention

No specific primary prevention for thymoma and thymic carcinoma is currently known. Because no clear environmental risk factors have been established, prevention by avoiding specific exposures is difficult.

However, the following clinical recommendations are important:

In MG patients, appropriate treatment with anticholinesterases, steroids, immunosuppressants and others is important for preventing MG crisis and improving quality of life. Adequate MG control before thymectomy helps reduce perioperative complications.


13. References